Neutropenia: antibiotic combinations for empiric therapy

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
L S Young

Abstract

During the last two decades the mortality from gram-negative septicemia in neutropenia patients with serious underlying disease has declined from 85% to less than 20%. Many factors seem responsible for this trend: (a) the development of potent broad-spectrum antimicrobial agents (b) aggressive clinical approaches to empiric therapy entailing the use of antibiotics before results of cultures are known. (c) better supportive care, (d) improved treatment of underlying disease. Controversy persists about the choice of "optimum" regimens: clinical studies to date show major differences in evaluation criteria, particularly in the definition of "response". The largest and most convincing studies of gram-negative bacteremia still favor the use of antibiotic combinations in patients with profound, persistent neutropenia.

References

Jan 1, 1978·Chemotherapy·E T AndersonW L Hewitt
Dec 31, 1987·The New England Journal of Medicine·UNKNOWN EORTC International Antimicrobial Therapy Cooperative GroupS H Zinner
Aug 28, 1986·The New England Journal of Medicine·L S Young
Sep 1, 1985·Archives of Internal Medicine·G P BodeyL Elting
Jul 1, 1985·The Journal of Antimicrobial Chemotherapy·L S Young
May 1, 1971·The Medical Clinics of North America·D ArmstrongA H Blevins
May 1, 1968·Archives of Internal Medicine·M A Freid, K L Vosti
Jan 1, 1971·Archives of Internal Medicine·R E BryantM G Koenig
Sep 1, 1984·The American Journal of Medicine·D J WinstonR P Gale
Feb 1, 1982·Clinical Endocrinology·G M BellA Doig
Jul 1, 1981·The Journal of Antimicrobial Chemotherapy·L S YoungW J Martin
May 1, 1980·The American Journal of Medicine·L J LoveP H Wiernik

❮ Previous
Next ❯

Citations

Aug 1, 1991·Annals of Hematology·D D'AntonioG Torlontano
Nov 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C ViscoliM Glauser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The Journal of Infectious Diseases
L S Young
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
EORTC International Antimicrobial Therapy Cooperative Group
Baillière's Clinical Haematology
C ViscoliD Rogers
© 2022 Meta ULC. All rights reserved